Dihydromyricetin (DHM) Powder research utility stems from its ability to cross the blood-brain barrier and interact with specific receptor sites, as well as its systemic influence on oxidative stress markers. Key Areas of Laboratory Investigation: GABAa Receptor Modulation: Dihydromyricetin (DHM) Powder is a primary subject in neuropharmacology for its role as a selective negative modulator of the GABAa receptor’s benzodiazepine site. Researchers study its ability to counteract the effects of ethanol and its potential in investigating alcohol-use disorder models. Ethanol Metabolism: Studies focus on Dihydromyricetin (DHM) Powder ability to upregulate the activity of alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) in the liver. This makes it a critical tool for exploring the acceleration of toxin clearance in metabolic research. Antioxidant Signaling: Laboratory research demonstrates that DHM activates the AMPK pathway and increases the expression of endogenous antioxidants like Superoxide Dismutase (SOD) and Glutathione (GSH), protecting cells from oxidative damage. Hepatoprotective Activity: DHM is examined for its ability to reduce pro-inflammatory cytokines such as TNF-$\alpha$ and IL-6, and its potential to inhibit lipid accumulation in hepatocytes (liver cells) in fatty-liver models. Chemical & Technical Specifications Property Specification Chemical Name (2R,3R)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-2,3-dihydrochromen-4-one Molecular Formula $C_{15}H_{12}O_{8}$ Molecular Weight 320.25 g/mol Purity ≥98% (HPLC Verified) CAS Number 27200-12-0 Appearance Fine White to Light Yellow Powder
